|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms E Walmsley
|
|
|
b)
|
Position/status
|
Chief
Executive Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.47
|
82.730
(personal contribution)
|
||
|
£16.47
|
204.873
(personal contribution)
|
||
|
£16.47
|
223.059
(personal contribution)
|
||
|
£16.47
|
82.730
(personal contribution)
|
||
|
£16.47
|
204.858
(personal contribution)
|
||
|
£16.47
|
223.045
(personal contribution)
|
||
|
£16.47
|
82.730
(matching shares)
|
||
|
£16.47
|
204.873
(matching shares)
|
||
|
£16.47
|
223.059
(matching shares)
|
||
|
£16.47
|
82.730
(matching shares)
|
||
|
£16.47
|
204.858
(matching shares)
|
||
|
£16.47
|
223.045
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
2,042.590
£16.47
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr R G Connor
|
|
|
b)
|
Position/status
|
President, Global Manufacturing & Supply
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.47
|
60.585
(personal contribution)
|
||
|
£16.47
|
139.194
(personal contribution)
|
||
|
£16.47
|
116.145
(personal contribution)
|
||
|
£16.47
|
60.585
(personal contribution)
|
||
|
£16.47
|
116.131
(personal contribution)
|
||
|
£16.47
|
60.585
(matching shares)
|
||
|
£16.47
|
139.194
(matching shares)
|
||
|
£16.47
|
116.145
(matching shares)
|
||
|
£16.47
|
60.585
(matching shares)
|
||
|
£16.47
|
116.131
(personal contribution)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
985.280
£16.47
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr L Debruyne
|
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.47
|
195.213
(personal contribution)
|
||
|
£16.47
|
195.199
(personal contribution)
|
||
|
£16.47
|
195.213
(matching shares)
|
||
|
£16.47
|
195.199
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
780.824
£16.47
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr S Dingemans
|
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.47
|
115.556
(personal contribution)
|
||
|
£16.47
|
270.551
(personal contribution)
|
||
|
£16.47
|
202.642
personal contribution)
|
||
|
£16.47
|
115.540
(personal contribution)
|
||
|
£16.47
|
270.537
(personal contribution)
|
||
|
£16.47
|
202.642
(personal contribution)
|
||
|
£16.47
|
115.556
(matching shares)
|
||
|
£16.47
|
270.551
(matching shares)
|
||
|
£16.47
|
202.642
(matching shares)
|
||
|
£16.47
|
115.540
(matching shares)
|
||
|
£16.47
|
270.537
(matching shares)
|
||
|
£16.47
|
202.642
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
2,354.936
£16.47
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr N Hirons
|
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.47
|
42.420
(personal contribution)
|
||
|
£16.47
|
100.034
(personal contribution)
|
||
|
£16.47
|
73.412
(personal contribution)
|
||
|
£16.47
|
42.420
(personal contribution)
|
||
|
£16.47
|
100.034
(personal contribution)
|
||
|
£16.47
|
73.398
(personal contribution)
|
||
|
£16.47
|
42.420
(matching shares)
|
||
|
£16.47
|
100.034
(matching shares)
|
||
|
£16.47
|
73.412
(matching shares)
|
||
|
£16.47
|
42.420
(matching shares)
|
||
|
£16.47
|
100.034
(matching shares)
|
||
|
£16.47
|
73.398
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
863.436
£16.47
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr S A Hussain
|
|
|
b)
|
Position/status
|
President, Global Pharmaceuticals
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.47
|
199.970
(personal contribution)
|
||
|
£16.47
|
236.389
(personal contribution)
|
||
|
£16.47
|
202.908
personal contribution)
|
||
|
£16.47
|
236.389
(personal contribution)
|
||
|
£16.47
|
202.894
(personal contribution)
|
||
|
£16.47
|
199.970
(matching shares)
|
||
|
£16.47
|
236.389
(matching shares)
|
||
|
£16.47
|
202.908
(matching shares)
|
||
|
£16.47
|
236.389
(matching shares)
|
||
|
£16.47
|
202.894
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
2,157.100
£16.47
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr B McNamara
|
|
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN:
US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 13 April 2017 on ADSs held in
the Company's 2009 Deferred Annual Bonus Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$41.81
|
82.979
(personal contribution)
|
||
|
$41.81
|
82.979
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
165.958
$41.81
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr D S Redfern
|
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.47
|
67.977
(personal contribution)
|
||
|
£16.47
|
127.311
(personal contribution)
|
||
|
£16.47
|
92.391
(personal contribution)
|
||
|
£16.47
|
67.977
(personal contribution)
|
||
|
£16.47
|
127.311
(personal contribution)
|
||
|
£16.47
|
92.377
(personal contribution)
|
||
|
£16.47
|
67.977
(matching shares)
|
||
|
£16.47
|
127.311
(matching shares)
|
||
|
£16.47
|
92.391
(matching shares)
|
||
|
£16.47
|
67.977
(matching shares)
|
||
|
£16.47
|
127.311
(matching shares)
|
||
|
£16.47
|
92.377
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,150.688
£16.47
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Ms C Thomas
|
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.47
|
91.499
(personal contribution)
|
||
|
£16.47
|
186.252
(personal contribution)
|
||
|
£16.47
|
139.061(personal
contribution)
|
||
|
£16.47
|
91.483
(personal contribution)
|
||
|
£16.47
|
186.252
(personal contribution)
|
||
|
£16.47
|
139.061
(personal contribution)
|
||
|
£16.47
|
91.499
(matching shares)
|
||
|
£16.47
|
186.252
(matching shares)
|
||
|
£16.47
|
139.061
(matching shares)
|
||
|
£16.47
|
91.483
(matching shares)
|
||
|
£16.47
|
186.252
(matching shares)
|
||
|
£16.47
|
139.061
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
1,667.216
£16.47
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr P C Thomson
|
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.47
|
62.146
(personal contribution)
|
||
|
£16.47
|
113.955
(personal contribution)
|
||
|
£16.47
|
87.545
(personal contribution)
|
||
|
£16.47
|
62.146
(matching shares)
|
||
|
£16.47
|
113.955
(matching shares)
|
||
|
£16.47
|
87.545
matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
527.292
£16.47
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Mr D E Troy
|
|
|
b)
|
Position/status
|
SVP & General Counsel
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in ADSs following the re-investment
of dividends paid to shareholders on 13 April 2017 on ADSs held in
the Company's 2009 Deferred Annual Bonus Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
$41.81
|
47.220
(personal contribution)
|
||
|
$41.81
|
106.319
(personal contribution)
|
||
|
$41.81
|
88.057
(personal contribution)
|
||
|
$41.81
|
47.220
(personal contribution)
|
||
|
$41.81
|
106.319
(personal contribution)
|
||
|
$41.81
|
88.044
(personal contribution)
|
||
|
$41.81
|
47.220
(matching shares)
|
||
|
$41.81
|
106.319
(matching shares)
|
||
|
$41.81
|
88.057
(matching shares)
|
||
|
$41.81
|
47.220
(matching shares)
|
||
|
$41.81
|
106.319
(matching shares)
|
||
|
$41.81
|
88.044
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
966.358
$41.81
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
|
a)
|
Name
|
Dr P J T Vallance
|
|
|
b)
|
Position/status
|
President,
R&D
|
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN:
GB0009252882
|
|
|
b)
|
Nature
of the transaction
|
Increase in notional interest in Ordinary Shares following the
re-investment of dividends paid to shareholders on 13 April 2017 on
Ordinary Shares held in the Company's 2009 Deferred Annual Bonus
Plan.
|
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
|
£16.47
|
134.685
(personal contribution)
|
||
|
£16.47
|
219.092
(personal contribution)
|
||
|
£16.47
|
151.043
(personal contribution)
|
||
|
£16.47
|
134.685
(personal contribution)
|
||
|
£16.47
|
219.092
(personal contribution)
|
||
|
£16.47
|
151.043
(personal contribution)
|
||
|
£16.47
|
134.685
(matching shares)
|
||
|
£16.47
|
219.092
(matching shares)
|
||
|
£16.47
|
151.043
(matching shares)
|
||
|
£16.47
|
134.685
(matching shares)
|
||
|
£16.47
|
219.092
(matching shares)
|
||
|
£16.47
|
151.043
(matching shares)
|
||
|
d)
|
Aggregated
information
Aggregated
volume Price
|
2,019.280
£16.47
|
|
|
e)
|
Date
of the transaction
|
2017-04-18
|
|
|
f)
|
Place
of the transaction
|
n/a
|
|
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: April
19, 2017
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|